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BACKGROUND: In the past 3 decades, the arterial switch procedure has replaced the atrial switch procedure as treatment of 
choice for transposition of the great arteries. Although survival is superior after the arterial switch procedure, data on preg-
nancy outcomes are scarce and transposition of the great arteries after arterial switch is not yet included in the modified World 
Health Organization classification of maternal cardiovascular risk.
METHODS AND RESULTS: The ROPAC (Registry of Pregnancy and Cardiac disease) is an international prospective regis-
try of pregnant women with cardiac disease, part of the European Society of Cardiology EURObservational Research 
Programme. Pregnancy outcomes in all women after an arterial switch procedure for transposition of the great arteries 
are described. The primary end point was a major adverse cardiovascular event, defined as combined end point of ma-
ternal death, supraventricular or ventricular arrhythmias requiring treatment, heart failure, aortic dissection, endocarditis, 
ischemic coronary events, and thromboembolic events. Altogether, 41 pregnant women (mean age, 26.7±3.9 years) were 
included, and there was no maternal mortality. A major adverse cardiovascular event occurred in 2 women (4.9%): heart 
failure in one (2.4%) and ventricular tachycardia in another (2.4%). One woman experienced fetal loss, whereas no neonatal 
mortality was observed.
CONCLUSIONS: Women after an arterial switch procedure for transposition of the great arteries tolerate pregnancy well, with a 
favorable maternal and fetal outcome. During counseling, most women should be reassured that the risk of pregnancy is low. 
Classification as modified World Health Organization risk class II seems appropriate.
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The first successful arterial switch procedure for patients with transposition of the great arter-ies (TGA) was reported in 1975 by Jatene and 
colleagues.1 It establishes a biventricular circulation, 
where the morphologic left ventricle supports the 
systemic circulation. This is in contrast to the previ-
ously performed atrial switch procedure, after which 
the morphologic right ventricle acts as a systemic 
ventricle. This systemic right ventricle is prone to fail, 
leading to heart failure and a diminished survival rate.2 
Therefore, for the past 30 years, the arterial switch 
has been the surgical approach of choice for TGA.3 
Consequently, the number of women after an arterial 
switch procedure for TGA reaching childbearing age 
is increasing, although not without complications. 
Neoaortic valve regurgitation, dilatation of the aor-
tic root, ischemia attributable to coronary reinsertion 
problems, ventricular dysfunction, and right ventric-
ular outflow tract obstruction have all been reported 
after the arterial switch.4 Because pregnancy poses a 
hemodynamic challenge to the maternal circulation, it 
might increase the risk for these complications. Data 
on the outcome of pregnancies in women after an 
arterial switch procedure are scarce. Single cases of 
successful pregnancies were reported in 2001 and 
2006,5,6 as well as retrospective series from single 
centers7–9 and one study from 2 centers.3 These re-
ported the outcome of pregnancies in 9, 10, 11, and 
15 women, respectively. The rate of adverse events 
differed significantly between these reports, whereas 
larger prospective studies are lacking, meaning that 
uncertainty remains about the impact of pregnancy 
in women after an arterial switch procedure.3,7–9 
Accordingly, TGA after an arterial switch procedure 
is not yet classified in the modified World Health 
Organization classification, the most commonly used 
disease-specific risk assessment of pregnancy in 
women with cardiac disease.10 Consequently, the 
aim of this study is to provide a much more accurate 
assessment of maternal and fetal outcomes of preg-
nancy in this group of women.
METHODS
Study Design
The ROPAC (Registry of Pregnancy and Cardiac dis-
ease) is an international, prospective, observational 
registry of pregnant patients with structural heart dis-
ease, including valvular and congenital heart disease, 
ischemic heart disease, aortic pathological features, 
and pulmonary arterial hypertension. Study design 
and methods have been described previously.11 The 
European Society of Cardiology working groups 
on congenital heart disease and valvular heart dis-
ease initiated ROPAC in 2007 and subsequently it 
was embedded in the EURObservational Research 
Programme of the European Society of Cardiology.
Ethical approval or Institutional Review Board ap-
proval as well as patients’ informed consent were ob-
tained if necessary, according to local requirements.
Pregnant women who were included in the 
ROPAC prospectively between January 2007 and 
January 2018 and had previously undergone an ar-
terial switch procedure for TGA were included in this 
study. The data that support the findings of this study 
are available from the corresponding author on rea-
sonable request.
Data
The ROPAC study protocol and the first results of 
this registry were published in 2013.11 Patients with 
a diagnosis of TGA treated with an arterial switch 
procedure were identified from the registry and 
compared with the rest of the total ROPAC cohort. 
Baseline characteristics collected before pregnancy 
CLINICAL PERSPECTIVE
What Is New?
• Women after arterial switch operation for trans-
position of the great arteries tolerate pregnancy 
well, on the basis of 41 pregnancies in a pro-
spective worldwide registry.
• In this cohort, there was no maternal mortality, 
and major adverse cardiovascular events oc-
curred in 4.9%, as heart failure (2.4%) and ven-
tricular tachycardia (2.4%).
• Prematurity (17.1%) was the most important 
fetal complication, followed by low birth weight 
(14.6%), but fetal loss occurred in only 2.4%.
What Are the Clinical Implications?
• Women after arterial switch for transposition 
of the great arteries can be counseled that 
pregnancy is safe, with a low risk of cardiac 
complications.
• Currently unclassified in the modified World 
Health Organization classification for maternal 
cardiovascular risk, this study suggests that 
pregnancy after arterial switch for transposition 
of the great arteries can be classified as modi-
fied World Health Organization risk class II.
Nonstandard Abbreviations and Acronyms
ROPAC Registry of Pregnancy and Cardiac 
disease
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included age, New York Heart Association functional 
class, ECG rhythm, diagnosis, risk factors (smoking 
habits, hypertension, and diabetes mellitus), medi-
cation, previous interventions, parity and obstetric 
history, and echocardiographic measurements. The 
provision of echocardiographic data was facultative. 
Countries were divided into developed or emerging 
countries, according to the International Monetary 
Fund Classification.12
Definitions and End Points
The primary combined end point was the occur-
rence of a major adverse cardiovascular event, 
defined as combined end point of maternal death, 
supraventricular or ventricular arrhythmias requiring 
treatment, heart failure, aortic dissection, endocar-
ditis, ischemic coronary event, and other thrombo-
embolic events. The secondary end points were 
adverse obstetric outcomes and adverse fetal/neo-
natal outcomes. Heart failure was defined accord-
ing to the American College of Cardiology/American 
Heart Association guidelines,13 and heart failure 
episodes were only included when they required 
hospital admission, new treatment, or change in 
the existing treatment regimen. Ventricular function 
was categorized as normal, mildly impaired, mod-
erately impaired, or severely impaired. Postpartum 
hemorrhage was defined as increased blood loss 
during delivery up to 24  hours postpartum, requir-
ing specific interventions. Hemolysis, elevated liver 
enzymes, low platelets syndrome, preeclampsia and 
eclampsia, and pregnancy-induced hypertension 
were defined according to the International Society 
for the Study of Hypertension in Pregnancy 2018 
statement.14 Fetal mortality was defined as the death 
of a fetus after 20  weeks of gestation until birth. 
Neonatal mortality was defined as the death of a 
live-born baby in the first 6 months of life. Premature 
birth was defined as birth before 37 weeks of gesta-
tion. Low birth weight was defined as a birth weight 
of <2500  g. Low Apgar score was defined as an 
Apgar score at 5 minutes of <7. All outcomes were 
examined for the duration of the pregnancy and up 
to 6 months postpartum.
Statistical Analysis
Data are presented as mean values with SD if nor-
mally distributed and median with interquartile range 
if skewed. Categorical data are presented as frequen-
cies and percentages. Baseline characteristics and 
outcomes were compared between women after 
arterial switch for TGA and the other pregnancies in 
the ROPAC cohort, using Student t tests and χ2 tests 
where appropriate. P<0.05 (2-sided test) was con-
sidered significant. All statistical tests and analyses 
were performed with SPSS version 21.0 (SPSS Inc, 
Chicago, IL).
RESULTS
There were 41 women after arterial switch for TGA 
among the 5739 patients included in ROPAC from 
January 2007 to January 2018.15 Baseline character-
istics are presented in Table  1. Their mean age was 
26.7±3.9 years, 21 women (51.2%) were primigravida, 
and 2 women (4.9%) were from an emerging country, 
as opposed to 40% in the rest of the ROPAC cohort 
(P<0.001). Most of the women (97.6%) were asymp-
tomatic or had only mild symptoms (New York Heart 
Association class I/II) before pregnancy. Only one 
woman was in New York Heart Association class 
III. Cardiac medication was used by 24.4% before 
pregnancy.
Maternal Outcomes
Maternal cardiac outcomes of pregnancy are presented 
in Table 2. There was no maternal mortality either in 
pregnancy or up to 6 months after delivery, whereas 
it occurred in 0.7% of the other ROPAC pregnancies 
(0% versus 0.7%; P=0.560). Hospital admission for 
a cardiac reason was required in one woman (2.4%) 
because of heart failure. The woman had a history of 
a Blalock-Taussig shunt before the arterial switch pro-
cedure and had experienced heart failure symptoms 
before pregnancy. Unfortunately, a prepregnancy 
echocardiogram was not available. She was delivered 
at 36  weeks gestation by an elective cesarean sec-
tion. In the third month postpartum, acute heart failure 
developed. At that point, left ventricular systolic func-
tion was moderately impaired, with an ejection fraction 
of 45%, without significant aortic or pulmonary valve 
dysfunction.
There were no cases of supraventricular tachy-
cardia, and ventricular tachycardia occurred in one 
woman (2.4%). In the rest of the ROPAC cohort, ven-
tricular tachycardia occurred in 1.6% (2.4% versus 
1.6%; P=0.652), whereas supraventricular tachycar-
dia occurred in 1.7% (0% versus 1.7%; P=0.404). 
Before her arterial switch procedure, this woman 
underwent banding of the pulmonary artery and a 
Blalock-Taussig shunt. Before pregnancy, echocar-
diography showed good biventricular function with-
out significant valve dysfunction. During the second 
and third trimesters, ventricular tachycardia and 
frequent ventricular ectopic beats occurred, which 
were effectively treated with metoprolol without re-
quiring hospital admission. After induction of labor at 
38 weeks of gestation, she had a vacuum-assisted 
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Table 1. Baseline Characteristics
Characteristic TGA After Arterial Switch (n=41) Other ROPAC (n=5698) P Value
Age, mean (SD), y 26.7 (3.9) 29.6 (5.6) 0.002
Living in an emerging country 2 (4.9) 2279 (40) <0.001
Primigravida 21 (51.2) 2552 (44.9) 0.420
Current smoking 1 (2.4) 227 (4.6) 0.617
Underlying cardiac pathological features
Associated cardiac defects
Ventricular septal defect 13 (31.7) 703 (12.3) <0.001
PDA 4 (9.8) 145 (2.5) 0.004
Coarctation of the aorta 2 (4.9) 301 (5.3) 0.129
Prior interventions/surgery
Arterial switch 41 (100) 41 (0.7) NA
Time since arterial switch, mean (SD), y 25.7 (0.7) NA NA
Ventricular septal defect closure 13 (31.7) 908 (15.9) 0.006
Pulmonary banding 12 (29.3) NA NA
Rashkind procedure/surgical atrial septostomy 9 (22.0) NA NA
Blalock-Taussig shunt 5 (12.2) NA NA
Pulmonary valve intervention* 4 (9.8) 230 (4) 0.065
Coarctation of aorta resection 2 (4.9) 272 (4.8) 0.150
Percutaneous coronary intervention 1 (2.4) 63 (1.1) 0.418
Aortic surgery 1 (2.4) 235 (4.1) 0.588
Dilatation of pulmonary artery stenosis 1 (2.4) NA NA
PDA closure 1 (2.4) NA NA
Prepregnancy cardiac status
Diabetes mellitus 0 (0) 90 (2) 0.412
Chronic hypertension 1 (2.4) 379 (6.8) 0.271
Signs of heart failure 1 (2.4) 595 (10.6) 0.090
Left ventricular ejection fraction <40% 1 (2.4) 252 (4.4) 0.538
Pulmonary hypertension 1 (2.4) 44 (0.8) 0.568
NYHA class
I 38 (92.7) 4169 (73.2) 0.005
II 2 (4.9) 1189 (20.9) 0.012
III 1 (2.4) 175 (3.1) 0.815
IV 0 (0) 28 (0.5) 0.653
Aortic stenosis 0 (0) 397 (7) 0.077
Aortic regurgitation 14 (34.1) 876 (15.4) <0.001
Mild 13 (31.7) 585 (10.4)
Moderate 1 (2.4) 236 (4.2)
Severe 0 (0) 55 (1)
Pulmonary stenosis 14 (34.1) 443 (8) <0.001
Aortic dilatation 4 (9.8) 170 (3) 0.012
Prepregnancy cardiac medication 10 (24.4) 2059 (36.1) 0.119
β Blockers 2 (4.9) 561 (9.8) 0.287
Diuretics 1 (2.4) 216 (3.8) 0.651
ACE inhibitor 2 (4.9) 155 (2.7) 0.399
Antiplatelet drugs 2 (4.9) 232 (4.1) 0.795
Drug name not included in database 3 (7.3) NA NA
Values are number (percentage) if not otherwise stated. ACE indicates angiotensin-converting enzyme; NA, not available; NYHA, New York Heart Association; 
PDA, persistent ductus arteriosus; ROPAC, Registry of Pregnancy and Cardiac disease; and TGA, transposition of the great arteries.
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On the basis of these 2 events, the total major ad-
verse cardiovascular event rate was 4.9%, and no 
other events or interventions occurred during preg-
nancy or in the 6-month follow-up after delivery. An 
echocardiographic assessment of ventricular systolic 
function before pregnancy or during the first trimes-
ter was available in 23 women (56.1%). Left ventricular 
systolic function was normal in 22 (95.7%), whereas it 
was moderately impaired in 1 (4.3%). Right ventricular 
systolic function was normal in 18 women (78.3%) and 
moderately impaired in 5 (21.7%). Serial data (prepreg-
nancy and postpartum) were available in 13 women 
(Figure  1). No deterioration in ventricular function or 
aortic valve function was observed.
Obstetric and Fetal Outcomes
Obstetric and fetal outcomes are presented in Table 3. 
Hypertensive disorders of pregnancy occurred in 2 
pregnancies (4.9%), compared with 4.4% of the rest of 
the ROPAC cohort (P=0.865). Median gestational age 
at delivery was 39  weeks (interquartile range, 37–40 
weeks), and mean birth weight was 2962.2±99.8 g, 
with low birth weight in 14.6% versus 11.7% (P=0.561) 
in the other ROPAC pregnancies. There were 7 pre-
mature births (17.1%) at a median gestational age of 
35 weeks (interquartile range, 34–36 weeks), of which 
5 were spontaneous labors and 2 were medically in-
duced for obstetric reasons. A cesarean section was 
performed in 46.3% of women after arterial switch for 
TGA, compared with 49.8% of the rest of the ROPAC 
cohort (P=0.662). Fetal death occurred once in our co-
hort (2.4%), and in 1.3% of the other women included 
in ROPAC (P=0.778).
DISCUSSION
The ROPAC, an international prospective registry, 
studies the outcomes of pregnancy in women with 
structural heart disease. In this article, we have fo-
cused on women with TGA treated with an arterial 
switch procedure, and our findings are summarized in 
Figure 2. Nearly all women tolerated pregnancy well, 
with a low rate of major adverse cardiovascular events 
(only 4.9%) and without maternal or neonatal mortal-
ity. Fetal mortality occurred in only one pregnancy, 
whereas in terms of maternal morbidity, heart failure 
and arrhythmias both also occurred only once.
Maternal Outcomes
This first large prospective study shows that maternal 
outcome is favorable, whereas by comparison in pre-
vious retrospective studies, maternal cardiac events 
occurred in 12% to 29% of women,3,8,9 although one 
recent study (n=15) reported no cardiac events at all.7 
Arrhythmias and heart failure were most frequently 
encountered in these older studies (Figure  3). The 
wide variation in the number of events is probably 
because of the small number of women included in 
these studies. Furthermore, some of these reports 
included women from an earlier surgical era and with 
a more severe prior clinical course.3,7 Indeed, both 
women with cardiac events in our study had had a 
Blalock-Taussig shunt before the arterial switch pro-
cedure, probably illustrating their more complex clini-
cal course.
Our contemporary prospective data are reassuring 
about maternal complications. This information is 
critically important for women with an arterial switch 
who are contemplating pregnancy, as they can now 
be reassured that their chance of complications is 
low. Because of the low number of events, an analysis 
to identify risk factors for adverse outcomes was not 
possible.
Most patients in our study had a normal left (95.7%) 
and right (78.3%) ventricular systolic function prepreg-
nancy. Furthermore, in the women with serial echocar-
diographic data, there was no deterioration in left or right 
ventricular function (Figure 1). In the study of Horiuchi and 
colleagues, 50% of women with a cardiac event during 
pregnancy and 20% of those without a cardiac event had 
Table 2. Maternal Outcomes of Pregnancy
Outcome TGA After Arterial Switch (n=41) Other ROPAC (n=5698) P Value
Maternal mortality ≤6 mo postpartum 0 (0) 40 (0.7) 0.590
Hospital admission for a cardiac reason 1 (2.4) 757 (13.3) 0.041
Heart failure 1 (2.4) 654 (11.5) 0.070
Supraventricular tachycardia 0 (0) 95 (1.7) 0.404
Ventricular tachycardia 1 (2.4) 89 (1.6) 0.652
Thromboembolic events 0 (0) 87 (1.5) 0.425
Endocarditis 0 (0) 33 (0.6) 0.625
Acute coronary syndrome 0 (0) 24 (0.4) 0.677
Aortic dissection 0 (0) 5 (0.1) 0.849
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a reduced left ventricular function.8 This might explain the 
higher number of cardiac events in their study. During 
follow-up, no further deterioration of left ventricular func-
tion was observed.8 Similar to our experience, Stoll and 
colleagues reported no adverse cardiac events, with all 
women having normal left ventricular systolic function 
before their first pregnancy, whereas one woman had 
a mildly impaired function after her second pregnancy.7 
Therefore, an echocardiogram before pregnancy is an 
important tool for risk assessment.
Figure 1. Echocardiographic prepregnancy and postpartum ventricular systolic function (A and B) and aortic valve function 
(C) in the women in whom serial echocardiographic data were available.
The postpartum echocardiogram was performed at a mean of 8.2 months postpartum (SD, 1.2 months), with a range of 1 to 15 months.
Table 3. Obstetric and Fetal Outcomes of Pregnancy
Outcome TGA After Arterial Switch (n=41) Other ROPAC (n=5698) P Value
Pregnancy-induced hypertension 0 (0) 77 (1.4) 0.454
(Pre) eclampsia or HELLP syndrome 2 (4.9) 170 (3) 0.478
Gestational diabetes mellitus 0 (0) 160 (2.8) 0.274
Postpartum hemorrhage 2 (4.9) 168 (2.9) 0.468
Cesarean section 19 (46.3) 2662 (49.8) 0.662
Emergency cesarean section 6 (14.6) 760 (13.3) 0.808
Emergency cesarean section for cardiac reason 0 (0) 132 (2.3) 0.324
Fetal death 1 (2.4) 71 (1.2) 0.778
Neonatal death 0 (0) 33 (0.6) 0.625
Fetal congenital heart disease 0 (0) 156 (2.7) 0.283
Premature birth 7 (17.1) 898 (18) 0.947
IUGR 1 (2.4) 253 (4.4) 0.535
Low Apgar scores 2 (4.9) 395 (6.9) 0.606
Low birth weight 6 (14.6) 667 (11.7) 0.561
Birth weight, mean (SD), g 2962.2 (99.8) 2970.9 (639.6) 0.941
Values are number (percentage), except for birth weight. HELLP indicates hemolysis, elevated liver enzymes, low platelet count; IUGR, intrauterine growth 
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In comparison to previous reports of pregnancy 
after the atrial switch procedure, which reported sev-
eral complications, most frequently arrhythmias and 
heart failure, with a rate between 7% and 22% and 
between 7% and 21%, respectively, depending on 
the study design and patient population,16–19 the ma-
ternal outcome in our cohort after the arterial switch 
procedure is much more favorable. These results 
emphasize the advantages of the later procedure 
further.
Obstetric and Fetal Outcomes
In our contemporary cohort, both obstetric and fetal 
complications were less frequent than reported by 
previous studies.8,9 Interestingly, the most recent 
Figure 2. Pregnancy outcomes in women after arterial switch operation for transposition of the 
great arteries.
VSD indicates ventricular septal defect.
Figure 3. Rate of adverse cardiovascular events in comparison to previously published reports.
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study reported an unexpected high incidence of ma-
ternal obstetric complications (58.8%).9 Most of these 
complications were attributable to postpartum hemor-
rhage, whereas this occurred in only 4.9% of women 
in our cohort. Maternal obstetric complications are not 
mentioned in detail in the other 2 series.3,7
The most frequent observed fetal complication 
in our study was premature birth (17.1%), followed 
by low birth weight (14.6%). Both are not signifi-
cantly different from the rest of the ROPAC cohort. 
Iatrogenic premature birth was because of obstet-
ric reasons and never because of cardiac causes. 
Although one fetal loss was observed, there was no 
neonatal mortality. Unfortunately, not all previous 
studies commented on the fetal outcome in detail. 
Stoll and colleagues reported premature birth in 9.1% 
of pregnancies,7 whereas in the series of Horiuchi 
and colleagues, 21% of pregnancies did not reach 
full term.8 In the latter study, low birth weight was 
observed in 27%,8 whereas Tobler et al reported a 
lower rate, with 14.3%.3 Therefore, the results of our 
study provide reassurance about the fetal outcome 
compared with previous literature.
A cesarean section was performed in 46.3% of 
women in our study, which is comparable to the high 
number of women with a cesarean section in the whole 
ROPAC cohort (49.8%; P=0.662). In the previous stud-
ies, the frequency of cesarean sections varied between 
36% and 47%.7–9 These high rates could be attributable 
to the congenital heart defect of the mother, because 
it is conceivable that women with heart disease in gen-
eral are handled with more care and apprehension by 
treating physicians and are thus given a cesarean sec-
tion (as many physicians prefer this apparently more 
controlled environment). This could be especially true 
for congenital heart defects, for which data on preg-
nancy outcomes are scarce as they are for patients 
with an arterial switch procedure for TGA. However, 
the available data do not support this approach,20 and 
guidelines recommend that a cesarean section should 
only be considered for obstetric indications or a lim-
ited number of cardiac indications, including labor on 
oral anticoagulants, aggressive aortic pathological fea-
tures, acute intractable heart failure, and severe pul-
monary hypertension.10 This is also reflected by the 
reassuringly low number (15%) of emergency cesarean 
sections in our study, none of which was attributable 
to cardiac reasons, which confirms the results of Stoll 
et al,7 whereas it is much lower than the recently re-
ported 63%.9 The last report had an unexpectedly high 
number of obstetric complications. In addition, the use 
of Cesarean section as a primary mode of delivery is 
country and center dependent and so could influence 
the numbers in our multicenter study.
Interestingly, only 4.9% of women from our cohort 
are living in an emerging country, as opposed to 40% 
of the rest of the ROPAC cohort (P<0.001). The main 
reason for this finding could be that the arterial switch 
procedure for TGA was often not available to children 
born in the developing world for a long period.21 In re-
cent years, this has changed,22 and therefore, we can 
expect an increase in the numbers of women after an 
arterial switch procedure for TGA reaching childbear-
ing age in these emerging countries.
A limitation of our study is that serial echocardio-
graphic data were available in only a limited number of 
women. Therefore, analysis on the course and outcome 
of ventricular function as well as aortic and pulmonary 
valve function, especially considering the neoaortic valve, 
was not possible in all women. Despite these limitations, 
this prospective registry included the largest number of 
women after an arterial switch procedure for TGA re-
ported to date, providing important information related to 
the maternal and fetal outcome in these women.
CONCLUSIONS
In conclusion, women after an arterial switch proce-
dure for TGA tolerate pregnancy well, with a favorable 
maternal and fetal outcome. Therefore, women after 
an arterial switch procedure for TGA should be coun-
seled that pregnancy is low risk. With a major adverse 
cardiac event rate of 4.9%, this corresponds to risk 
class modified World Health Organization II.
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